Have You Heard? (Spring 2022)

View ADA No Surprises Act (NSA) Webinar to Avoid Being Caught Off Guard by NSA Requirements for Audiologists
As of January 2022, the federal No Surprises Act (NSA) requires health care providers, including audiologists, to alert patients to potential out-of-network charges and give uninsured and self-pay patients an upfront cost estimate, among many other policy changes.

Avoid costly surprises for your practice—This live session will provide a comprehensive overview of NSA provisions and key information that audiologists need to know to stay compliant with its provisions. Template forms will also be available for ADA members after the event.

Learning Outcomes
Upon completion of the course, attendees will be able to:
  • Describe new requirements for health care providers and how those requirements will affect provider reimbursement and costs for patients
  • List the pricing information that audiologists must provide to self-pay and uninsured patients,
  • Describe when and how the information provided by audiologists to self-pay and uninsured patients must be provided
Course Leaders
Daphne Kackloudis is a healthcare attorney at Brennan, Manna, & Diamond (BMD), where she leads the firm’s Columbus, Ohio healthcare practice. She specializes in health care service delivery and payment systems.
Ashley Watson, Esq., is a healthcare attorney in BMD's Columbus office. Her expertise includes healthcare public policy and regulatory compliance and healthcare program operations.
Visit www.audiologist.org for more information.    
National Clinical Trial Presents Opportunities for Audiologists and Patients
ADA is pleased to share exciting news of a broad national clinical trial that may benefit both you and your patients by helping you personalize your care even further. Emerging new drug therapies may enable audiologists to help patients improve speech clarity. One such drug candidate is FX-322, a regenerative therapy that has already shown clinically significant results in trials. A national clinical trial, led by Frequency Therapeutics, will investigate a single dose of FX-322, delivered via injection through the eardrum on the round window where it diffuses into the cochlea.

Frequency Therapeutics is looking to recruit subjects into the trial and is asking audiologists from around the country to refer patients into this important study. With 30 sites across the country, it’s likely there is a trial site close to your practice. If not, your patients may still participate and will be compensated to travel. Qualifying referrals will be screened at one visit, then accepted subjects will return for six additional visits.

Patients qualifying for referral into the trial must:
  • Be between the ages of 18 and 65 years of age
  • Have a documented medical history of acquired, adult-onset, sensorineural hearing loss associated with noise-induced SNHL or sudden onset SNHL
  • Have had a hearing test (audiogram) at least 6 months ago or longer showing a pure-tone average (500, 1000, 2000 and 4000 Hz) between 35 and 85 dBHL
Knowledge of new and innovative treatment options add to the value audiologists provide to patients and reinforce the role of audiology as a clinical doctoring profession. A future where pharmaceuticals add to hearing intervention possibilities will provide new opportunities for audiologists and align with ADA’s entrepreneurial spirit. Visit www.clarahealth.com/studies/hearing-study for more information. If you have additional questions, please contact Dr. Kevin Franck at kfranck@frequencytx.com.